These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 36366502)

  • 1. Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies.
    Degasperi E; Anolli MP; Lampertico P
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
    Wong GLH; Gane E; Lok ASF
    J Hepatol; 2022 Jun; 76(6):1249-1262. PubMed ID: 35589248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on hepatitis B virus infection.
    You CR; Lee SW; Jang JW; Yoon SK
    World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus.
    Kim SW; Yoon JS; Lee M; Cho Y
    Clin Mol Hepatol; 2022 Jan; 28(1):17-30. PubMed ID: 34281294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference
    Cornberg M; Lok AS; Terrault NA; Zoulim F;
    J Hepatol; 2020 Mar; 72(3):539-557. PubMed ID: 31730789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward a Functional Cure for Hepatitis B.
    Lok ASF
    Gut Liver; 2024 Jul; 18(4):593-601. PubMed ID: 38533651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we cure hepatitis B virus with novel direct-acting antivirals?
    Martinez MG; Villeret F; Testoni B; Zoulim F
    Liver Int; 2020 Feb; 40 Suppl 1():27-34. PubMed ID: 32077597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.
    Moini M; Fung S
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A 2020 update on the progress of treatment and new drug clinical trials for hepatitis B].
    Jia JD; Niu JQ; You H; Kong YY; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):97-101. PubMed ID: 33685074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials.
    Hui RW; Mak LY; Seto WK; Yuen MF
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):127-140. PubMed ID: 35511483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical cure of hepatitis B: consensus and controversy].
    Hou JL; Wei L; Wang GQ; Jia JD; Duan ZP; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):636-639. PubMed ID: 32911898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine.
    Colombatto P; Coco B; Bonino F; Brunetto MR
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of different viral biomarkers on the management of chronic hepatitis B.
    Mak LY; Hui RW; Fung J; Seto WK; Yuen MF
    Clin Mol Hepatol; 2023 Apr; 29(2):263-276. PubMed ID: 36655304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A short half-life of cccDNA offer or ignite hope for hepatitis B cure under nucleos(t)ide analogues treatment].
    Gao L; Mao TH; Peng SW; Wang J; Chen XM; Lu FM
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jan; 30(1):99-102. PubMed ID: 35152678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated immunotherapy against chronic hepatitis B virus infection.
    Gao Y; Zhang TY; Yuan Q; Xia NS
    Hum Vaccin Immunother; 2017 Aug; 13(8):1768-1773. PubMed ID: 28521640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Perspectives on Development of Curative Strategies for Chronic Hepatitis B.
    Feld JJ; Lok AS; Zoulim F
    Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2040-2050. PubMed ID: 37080262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.